Association between dopaminergic genes (SLC6A3 and DRD2) and stuttering among Han Chinese

Journal of Human Genetics

Volumn 54, Issue 8, 2009, Pages 457-460

  Lan, Jie ^a   Song, Manshu ^b   Pan, Chunhui ^a   Zhuang, Guoqing ^a   Wang, Youxin ^b   Ma, Wenzhan ^a   Chu, Qiaoyun ^a   Lai, Qingxuan ^a   Xu, Feng ^a   Li, Yanli ^a   Liu, Lixin ^a   Wang, Wei ^a,b,c  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CURTIN UNIVERSITY   (Australia)

Author keywords

Case control study; Disorder of fluent speech; Dopamine D2 receptor; Dopamine transporter; Han Chinese; SNPs

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; GENOMIC DNA; SEROTONIN TRANSPORTER; SLC6A3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOPAMINERGIC ACTIVITY; FEMALE; GENDER; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SPEECH; SPEECH DISORDER; STUTTERING;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHINA; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D2; STUTTERING; YOUNG ADULT;

EID: 69349084678     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1038/jhg.2009.60     Document Type: Article

References (23)

1. Saussure, F. D. Course in General Linguistics (P. Owen, London, 1960).
2. Dell, G. A spreading activation theory of retrieval in language production. Psychol. Rev. 93, 283-321 (1986).
3. Levelt, W. Models of word production. Trends. Cogn. Sci. 3, 223-232 (1999).
4. Bloodstein, O. A Handbook on Stuttering (Singular Pub. Group, San Diego, California, 1997).
5. Costa, D. & Kroll, R. Stuttering: an update for physicians. Can. Med. Assoc. J. 162, 1849-1855 (2000).
6. Comings, D. E., Wu, S., Chiu, C., Ring, R. H., Gade, R., Ahn, C. et al. Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: The additive and subtractive effect of the three dopaminergic genes-DRD2, D-beta-H, and DAT1. Am. J. Med. Genet. 67, 264-288 (1996).
7. Maguire, G., Riley, G., Franklin, D., Maguire, M., Nguyen, C. & Brojeni, P. Olanzapine in the treatment of developmental stuttering: a double-blind, placebo-controlled trial. Ann. Clin. Psychiatry 16, 63-67 (2004).
8. Maguire, G. A., Yu, B. P., Franklin, D. L. & Riley, G. D. Alleviating stuttering with pharmacological interventions. Expert Opin. Pharmacother. 5, 1565-1571 (2004).
9. Wu, J. C., Maguire, G., Riley, G., Lee, A., Keator, D., Tang, C. et al. Increased dopamine activity associated with stuttering. Neuroreport 8, 767-770 (1997). (Pubitemid 27128233)
10. Goberman, A. M. & Blomgren, M. Parkinsonian speech disfluencies: effects of L-dopa-related fluctuations. J. Fluency Disord. 28, 55-70 (2003). (Pubitemid 36438619)
11. Kent, L. The use of tranquilizers in the treatment of stuttering. J Speech Hear Disord 28, 288-294 (1963).
12. Maguire, G. A., Gottschalk, L. A., Riley, G. D., Franklin, D. L., Bechtel, R. J. & Ashurst, J. Stuttering: Neuropsychiatric features measured by content analysis of speech and the effect of risperidone on stuttering severity. Compr. Psychiat. 40, 308-314 (1999).
13. Stager, S. V., Calis, K., Grothe, D., Bloch, M., Berensen, N. M., Smith, P. J. et al. Treatment with medications affecting dopaminergic and serotonergic mechanisms: Effects on fluency and anxiety in persons who stutter. J. Fluency Disord. 30, 319-335 (2005). (Pubitemid 41745019)
14. Maguire, G. A., Riley, G. D., Franklin, D. L. & Gottschalk, L. A. Risperidone for the treatment of stuttering. J. Clin. Psychopharmacol. 20, 479-482 (2000).
15. Healey, E. C. & Reid, R. ADHD and stuttering: a tutorial. J. Fluency Disord. 28, 79-93 (2003).
16. Mazei-Robison, M. S., Couch, R. S., Shelton, R. C., Stein, M. A. & Blakely, R. D. Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology 49, 724-736 (2005).
17. Bowton, E., Mazei-Robison, M., Blakely, R. & Galli, A. Dopamine transporter coding variant Ala559Val associated with attention deficit hyperactivity disorder (ADHD) causes alteration of dopamine efflux. FENS Forum Abstracts 3, A060.4 (2006).
18. Rodriguez-Jimenez, R., Hoenicka, J., Jimenez-Arriero, M. A., Ponce, G., Bagney, A., Aragues, M. et al. Performance in the Wisconsin card sorting test and the C957T polymorphism of the DRD2 gene in healthy volunteers. Neuropsychobiology 54, 166-170 (2006).
19. Ryan, B. P. Programmed Therapy for Stuttering in Children and Adults (Thomas, Springfield, IL, 1974).
20. Shi, Y. Y. & He, L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15, 97-98 (2005).
21. Bosshardt, H. Effects of concurrent cognitive processing on the fluency of word repetition: comparison between persons who do and do not stutter. J. Fluency Disord. 27, 93-114 (2002). (Pubitemid 34563313)
22. Kellendonk, C., Simpson, E., Polan, H., Malleret, G., Vronskaya, S., Winiger, V. et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49, 603-615 (2006). (Pubitemid 43221894)
23. Hirvonen, M., Laakso, A., Någren, K., Rinne, J., Pohjalainen, T. & Hietala, J. C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo. Mol. Psychiatr. 9, 1060-1061 (2004).